Combining personalized neoantigen vaccination with chemotherapy and anti-PD-1 to treat NSCLC

Leung, Carol Sze Ki;Van den Eynde, Benoit
(2022) Cancer Cell — Vol. 40, n° 9, p. 903-905 (2022)

Files

CancercellPreview20230220repository.pdf
  • Open Access
  • Adobe PDF
  • 219.93 KB
Download

Details

Authors
Abstract
In this issue of Cancer Cell, Awad et al. report a phase 1b clinical trial combining a personalized vaccine NEO-PV-01 with chemotherapy and anti-PD-1 pembrolizumab in firstline metastatic non-squamous NSCLC. They demonstrate this treatment regimen was well tolerated and induced neoantigen-specific CD4+ T-cell responses with effector phenotype.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Leung, C. S. K., & Van den Eynde, B. (2022). Combining personalized neoantigen vaccination with chemotherapy and anti-PD-1 to treat NSCLC. Cancer Cell, 40(9), 903-905. https://doi.org/10.1016/j.ccell.2022.08.002 (Original work published 2022)